Instructions for Liprimar (Atorvastatin)
English product name
Liprimar®
Release form
tab. film sheath, 10 mg: 14, 28, 30, 35, 50, 56 or 100 pcs.
tab. film sheath, 20 mg: 14, 28, 30, 35, 50, 56 or 100 pcs.
tab. film sheath, 40 mg: 14, 28, 30, 35, 50, 56 or 100 pcs.
tab. film sheath, 80 mg: 14, 28, 30, 35, 50, 56 or 100 pcs.
Description
The tablets, which are coated with a white film shell, are elliptical, with an engraving of "10" on one side and "PD 155" on the other side; the core of the tablets on the fracture is white.
1 tab.
atorvastatin (in the form of calcium atorvastatin) 10 mg
Auxiliary substances: calcium carbonate, cellulose microcrystalline, lactose monohydrate, sodium croskarmellose, polysorbate 80, hyprolosis, magnesium stearate; film shell: white YS-1-7040 (contains hypromellose, macrogol, titanium dioxide, talc), simethicone emulsion (cimeticon, stearin emulsifier, sorbic acid, water), herbal wax.
ATC codes
C10AA05 Atorvastatin
Clinical-pharmacological groups / Group affiliation
Hypolipidemic drug
Active substance
atorvastatin
Pharmacotherapy group Liprimar
Hypolipidemic agent - reductase inhibitor GMG-CoA
Storage Conditions Atorvastatin
The drug should be stored in a place inaccessible to children at a temperature not higher than 25 ° C.
Best before date Atorvastatin
The shelf life is three years. Do not apply after the expiry date indicated on the package.
Testimony Liprimar
Hypercholesterolemia:
as a supplement to the diet to reduce elevated total cholesterol, C-LDL, apo-B and triglycerides in adults, adolescents and children aged 10 years or older with primary hypercholesterolemia, including familial hypercholesterolemia (heterozygous variant) or combined (mixed) hyperlipidemia (respectively type IIa and IIb according to Fredrikson's classification) when the response to diet and other non-medicamentous treatments is insufficient;
to reduce elevated total cholesterol, HS-LDL in adults with homozygous familial hypercholesterolemia as a supplement to other hypolipidemic treatments (e.g. LDL-apheresis) or if such treatments are not available.
Prevention of cardiovascular diseases:
Prevention of cardiovascular events in adult patients at high risk of developing primary cardiovascular events as a supplement to the correction of other risk factors;
secondary prevention of cardiovascular complications in patients with IBS in order to reduce mortality, myocardial infarction, strokes, repeated hospitalizations for angina pectoris and the need for revascularization.
Method of use, course and dosage Liprimar
The drug Atorvastatin is ingested at any time of the day, regardless of food intake.
Before starting treatment with Liprimar®, you should try to control hypercholesterolemia through diet, exercise and weight loss in obese patients, as well as therapy for the underlying disease.
When prescribing the drug, the patient should be recommended a standard hypocholesterolemic diet, which he should follow throughout the entire period of therapy.
- Nosology (ICD codes)
- E78.0
- Pure hypercholesterolemia
- E78.2
- Mixed hyperlipidemia
- I20
- Angina [breast toad]
- I21
- Acute myocardial infarction
- I63
- Brain infarction
Pharmacological effect Liprimar
Synthetic hypolipidemic agent. Atorvastatin is a selective competitive inhibitor of GMG-CoA reductase, a key enzyme that converts 3-hydroxy-3-methylglutaryl-CoA into mevalonate, a precursor to steroids including cholesterol.
In patients with homozygous and heterozygous familial hypercholesterolemia, non-familial forms of hypercholesterolemia and mixed dyslipidemia, atorvastatin reduces blood plasma concentrations of total cholesterol (Hs), low-density lipoprotein cholesterol (Hs-LDL) and apolipoprotein B (apo-B), as well as very low-density lipoprotein cholesterol (Hs-LDL) and triglycerides (TH), and increases cholesterol concentrations of cholesterol-lowering proteins high density (Hs-HDL).
